Amycretin vs Semaglutide
Comparing Novo Nordisk's unimolecular GLP-1/amylin dual agonist amycretin with single-target semaglutide.
Last updated: February 1, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Amycretin
Dossier overview
Semaglutide
Dossier overview
Overview
Amycretin is Novo Nordisk’s investigational unimolecular dual GLP-1/amylin receptor agonist. Unlike CagriSema (which combines two separate peptides), amycretin is a single molecule designed to activate both pathways. This represents a next-generation approach to obesity treatment.
Mechanism Comparison
| Aspect | Amycretin | Semaglutide |
|---|---|---|
| Targets | GLP-1 + Amylin receptors | GLP-1 receptor only |
| Molecule Type | Unimolecular dual agonist | Single agonist |
| Design | Single peptide, dual activity | GLP-1 analog |
| Satiety Pathways | Hypothalamus + Area postrema | Primarily hypothalamus |
Unimolecular Advantage
Amycretin’s single-molecule approach potentially offers:
- Simplified dosing (one injection vs two)
- Balanced receptor activation
- Consistent pharmacokinetics
- Manufacturing advantages over combinations
Evidence Comparison
| Aspect | Amycretin | Semaglutide |
|---|---|---|
| Development Phase | Phase 1/2 | FDA Approved |
| Human Data | Early-stage | Extensive |
| Publication Status | Conference data | Peer-reviewed |
| Regulatory Status | Investigational | Approved globally |
Early Clinical Data
Phase 1 Results (Conference Data)
| Timeframe | Amycretin Weight Loss |
|---|---|
| 12 weeks | ~13% |
| Projected annualized | ~25% (extrapolated) |
Important caveats:
- Phase 1 data with small sample size
- Short duration
- No placebo comparison in all cohorts
- Extrapolations are speculative
Semaglutide 2.4mg (STEP 1)
| Metric | Result |
|---|---|
| Weight Loss (68 weeks) | ~15% |
| Peak weight loss | ~17% (continued effect) |
Regulatory Status
| Aspect | Amycretin | Semaglutide |
|---|---|---|
| FDA Status | Investigational (early) | Approved |
| Phase | 1/2 | N/A (marketed) |
| Expected Timeline | 2027+ (if successful) | Available now |
| Priority | Pipeline asset | Commercial product |
Potential Advantages of Amycretin
| Factor | Amycretin | Semaglutide | CagriSema |
|---|---|---|---|
| Injections | 1 | 1 | 1 (fixed combo) |
| Molecules | 1 | 1 | 2 |
| Dual pathway | Yes | No | Yes |
| Development stage | Early | Approved | Late-stage |
Side Effect Profile (Preliminary)
| Effect | Amycretin (Early Data) | Semaglutide |
|---|---|---|
| Nausea | Common | Common |
| Vomiting | Common | Common |
| GI Tolerability | Being evaluated | Well-characterized |
| Discontinuation | TBD | ~7% in trials |
Early data suggests typical incretin-class GI effects; full safety profile not yet established.
Strategic Context
Novo Nordisk Pipeline
| Compound | Type | Timeline |
|---|---|---|
| Semaglutide | Approved | Now |
| CagriSema | Combination (late-stage) | 2025-2026 |
| Amycretin | Next-gen unimolecular | 2027+ |
Amycretin represents the next wave after CagriSema.
Competitive Landscape
| Approach | Examples |
|---|---|
| GLP-1 only | Semaglutide, liraglutide |
| GLP-1/GIP | Tirzepatide |
| GLP-1/Glucagon | Survodutide, mazdutide |
| GLP-1/Amylin combo | CagriSema |
| GLP-1/Amylin unimolecular | Amycretin |
| Triple agonist | Retatrutide |
Key Differences
- Molecule design: Amycretin is one peptide vs semaglutide’s single-target approach
- Dual pathways: Amycretin activates both GLP-1 and amylin receptors
- Development stage: Semaglutide is proven; amycretin is experimental
- Efficacy potential: Early amycretin data suggests possibly greater weight loss
- Risk profile: Amycretin has limited safety data; semaglutide extensively characterized
Summary
- Amycretin is a promising next-generation unimolecular GLP-1/amylin agonist with impressive early data
- Semaglutide is the established, FDA-approved GLP-1 agonist with proven CV benefit
- Early amycretin data shows potentially superior weight loss, but requires confirmation
- Years of development separate amycretin from potential approval
- Single-molecule design may offer advantages over combination approaches
This comparison is for educational purposes only. Amycretin is in early-stage investigation. Clinical efficacy and safety not yet established. Consult a healthcare provider for treatment decisions.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.